Doctors order a PSEN1 genetic test when a patient develops dementia at age 65 or younger and has close relatives with a similar history of early dementia. PSEN1 stands for presenilin 1, a gene whose mutations are the most common known cause of early-onset familial Alzheimer's disease, so clinicians screen it before looking at the related genes PSEN2 and APP, according to GuidelineCentral's clinical genetics summary. The test itself is one piece of a larger workup, not a stand-alone diagnosis. A positive result confirms a genetic cause but still has to be paired with brain scans, spinal fluid tests, and cognitive exams to show that Alzheimer's pathology is actually present.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Gets Referred for PSEN1 Testing
- How Insurance Coverage Shapes the Order
- What a Positive or Negative Result Actually Means
- How Doctors Build the Full Workup Around the Gene
- Protecting Patients Before They Test
- Frequently Asked Questions
Who Gets Referred for PSEN1 Testing
Doctors reserve PSEN1 sequencing for a specific pattern: dementia symptoms starting at or before age 65, combined with an autosomal dominant family history — meaning dementia has appeared across multiple generations, consistent with a single inherited gene being passed down. This is the pattern GuidelineCentral's summary of the clinical genetics chapter describes as the trigger for ordering the test. The gene is not useful as a broad screening tool.
Lab Tests Online UK and pathologytestsexplained.org.au both state that PSEN1 testing has no role in general population screening or in typical late-onset Alzheimer's, which makes up the vast majority of cases. The test is built for the much smaller group of patients whose family history points to a dominant inherited form. Diagnostic yield rises the younger the patient and the stronger the family history. GuidelineCentral's summary notes that testing returns the most answers in patients under 60 who have another affected relative, especially a parent who developed the same early symptoms.
How Insurance Coverage Shapes the Order
Coverage rules often determine whether a doctor can order the test at all. Highmark's commercial medical policy limits PSEN1, PSEN2, and APP testing in symptomatic patients to those with dementia onset at 65 or younger who also have a first- or second-degree relative with a confirmed mutation, per Highmark's medical policy L-175-004.
That same policy requires genetic counseling both before and after the test, for every patient. Predictive testing — checking a currently healthy relative for the family's known mutation — carries its own rule: the policy requires the person be at least 18 years old.
- Symptomatic patient: dementia onset at 65 or younger, plus a relative with a confirmed mutation
- Asymptomatic relative: must be 18 or older to pursue predictive testing
- Both paths: pre-test and post-test genetic counseling required under Highmark's policy
What a Positive or Negative Result Actually Means
A positive PSEN1 result confirms an inherited cause but does not tell a patient when symptoms will start or how severe they will be. Lab Tests Online UK notes that penetrance and clinical expression vary even among people who carry the identical variant, which is why doctors read the genetic result alongside cognitive testing rather than treating it as a complete forecast. The Dominantly Inherited Alzheimer Network (DIAN), run through Washington University, treats PSEN1 mutations as deterministic and nearly fully penetrant — meaning almost everyone who carries one eventually develops the disease — with an age of onset that tends to run close to the pattern already seen in that family, according to DIAN's investigator resources.
DIAN enrolls known or suspected carriers in long-term studies combining clinical exams, genetics, MRI, and PET imaging. Even the imaging picture is not uniform across carriers. A DIAN study of 206 mutation carriers found that amyloid burden on PET scans varies substantially depending on the specific PSEN1 variant a person carries, while cerebrospinal fluid amyloid-beta 42 levels do not track the same way, according to the DIAN amyloid study. That means a doctor cannot treat a PET scan result and a spinal fluid result as interchangeable confirmations of the same thing — each test captures something the other misses.
How Doctors Build the Full Workup Around the Gene
PSEN1 sequencing rarely stands alone. Case reports documented at UKE Hamburg and in a published case study describe clinicians combining the genetic test with neuropsychological testing, brain MRI, cerebrospinal fluid biomarkers (amyloid-beta 42, tau, and phosphorylated tau), and amyloid PET imaging using tracers such as florbetapir or Pittsburgh Compound B. Each piece answers a different question: Together, these findings let a doctor say with confidence that a patient's dementia reflects Alzheimer's disease specifically, caused by a mutation that explains why it struck decades earlier than typical.
- Neuropsychological testing measures the pattern and severity of cognitive loss
- Brain MRI checks for structural changes and rules out other causes, such as strokes or tumors
- CSF biomarkers and amyloid PET confirm that Alzheimer's-type plaque and tangle pathology is actually present
- PSEN1 sequencing identifies the inherited cause driving that pathology
Protecting Patients Before They Test
Family pressure around genetic testing is common enough that genetic-counseling guidance addresses it directly. Counselors are advised to screen for coercion — cases where relatives are pushing a symptomatic family member toward testing against their own wishes — and to recommend against testing if the patient shows reluctance, offering DNA banking as an alternative, according to GuidelineCentral's clinical genetics summary.
DNA banking stores a sample for possible future testing without forcing a decision in the moment. This gives a hesitant patient room to decide later, while still preserving the option for relatives who may want answers for their own family planning.
Frequently Asked Questions
Can a healthy person with no symptoms get tested if a parent had a confirmed PSEN1 mutation?
Yes, through predictive testing, which Highmark's policy requires be limited to people 18 or older, alongside pre- and post-test genetic counseling.
Does a negative PSEN1 result rule out early-onset Alzheimer's?
Not fully — labs also check PSEN2 and APP, since PSEN1 is only the most common of several known genetic causes, per GuidelineCentral's summary.
Why do doctors need both a PET scan and a spinal fluid test if someone already has a positive PSEN1 result?
Because DIAN's research on 206 carriers found PET-measured amyloid and CSF amyloid-beta 42 don't move together, so each test adds information the other doesn't capture.
